These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 30550256)
21. Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior. Racine E; Sattler S; Boehlen W Sci Eng Ethics; 2021 Mar; 27(2):19. PubMed ID: 33759032 [TBL] [Abstract][Full Text] [Related]
22. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles]. Metzinger TK Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814 [TBL] [Abstract][Full Text] [Related]
23. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Barak S; Weiner I Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999 [TBL] [Abstract][Full Text] [Related]
24. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Boot BP; Partridge B; Hall W Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842 [TBL] [Abstract][Full Text] [Related]
25. Attitudes Toward Cognitive Enhancement: The Role of Metaphor and Context. Conrad EC; Humphries S; Chatterjee A AJOB Neurosci; 2019; 10(1):35-47. PubMed ID: 31070552 [TBL] [Abstract][Full Text] [Related]
27. Ampakines and the threefold path to cognitive enhancement. Lynch G; Gall CM Trends Neurosci; 2006 Oct; 29(10):554-62. PubMed ID: 16890999 [TBL] [Abstract][Full Text] [Related]
28. The potential of HDAC inhibitors as cognitive enhancers. Gräff J; Tsai LH Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310 [TBL] [Abstract][Full Text] [Related]
29. A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. Kehagia AA J Psychopharmacol; 2016 Oct; 30(10):957-66. PubMed ID: 27604630 [TBL] [Abstract][Full Text] [Related]
31. [Neuroenhancement in healthy subject? A French case study]. Micoulaud-Franchi JA; Vion-Dury J; Lancon C Therapie; 2012; 67(3):213-21. PubMed ID: 22874487 [TBL] [Abstract][Full Text] [Related]
32. Effects of transcranial electrical stimulation on cognition. Kuo MF; Nitsche MA Clin EEG Neurosci; 2012 Jul; 43(3):192-9. PubMed ID: 22956647 [TBL] [Abstract][Full Text] [Related]
33. [Hippocampus: a target for cognition enhancers]. Arushanian EB; Beĭer EV Eksp Klin Farmakol; 2007; 70(4):59-65. PubMed ID: 18078044 [TBL] [Abstract][Full Text] [Related]
34. The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates. Koren G; Korn L J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):100-102. PubMed ID: 33666399 [TBL] [Abstract][Full Text] [Related]
39. Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: implications for low dose clinical efficacy. Werkheiser JL; Sydserff S; Hubbs SJ; Ding M; Eisman MS; Perry D; Williams AJ; Smith JS; Mrzljak L; Maier DL Neuroscience; 2011 Jul; 186():76-87. PubMed ID: 21550383 [TBL] [Abstract][Full Text] [Related]